Cardiac Science Announces 1999 Year End Results.

Business Editors/Health & Medical Writers

BIOWIRE2K

IRVINE, Calif.--(BW HealthWire)--March 30, 2000

Cardiac Science Inc. (OTC Bulletin Board:DFIB), the developer of Powerheart(R) ECD(TM), the only hospital monitor that provides life-saving defibrillation within seconds and without the aid of hospital staff, reported revenues of $102,900 and a net loss of $7,719,759, or 85 cents a share, for the year ended December 31, 1999 as compared to no revenues and a net loss of $4,438,734, or 81 cents a share for the year ended December 31, 1998. R&D expenses relating to the development of the commercial version of the Powerheart defibrillator-monitor totaled approximately $4,000,000 or 52 percent of the loss from continuing operations for the year ending December 31, 1999.

For the quarter ended December 31, 1999, the company reported revenues of $102,900 and a net loss of $2,890,867, or 25 cents a share, as compared to no revenues and a net loss of $1,840,887, or 31 cents a share for the quarter ended December 31, 1998.

"Through the strong financial support of our stockholders and the collective efforts of our tenacious employees, Cardiac Science achieved its objectives in 1999. We completed the development of our initial product, received U.S and European regulatory clearances and made our first commercial shipment of Powerhearts. We also expanded our strategic partnership with Medtronic Physio-Control and established a strong independent distribution network, which now encompasses over 40 countries worldwide," said Raymond W. Cohen, president and chief executive officer. "Cardiac Science is a company with clear vision and a focused business plan. Our near term strategy is to actively encourage the marketplace to adopt the Powerheart, grow revenues and drive utilization of our proprietary disposable defibrillation electrodes. To realize the full potential of our vision, we are investing significant resources to market the Powerheart and to develop new embodiments of fully automatic defibrillation products which utilize our core technology. To that end, we will continue to pursue discussions with manufacturers interested in integrating and licensing our proprietary RHYTHMx ECD(TM) cardiac arrest detection and defibrillation module into their patient monitoring systems."

About Cardiac Science

Cardiac Science develops and markets life-saving external cardiac defibrillator devices and proprietary tachyarrhythmia detection software that monitor and automatically treat cardiac arrest patients. Cardiac Science began shipments of its initial commercial product, the Powerheart, on Dec. 31, 1999.

Powerheart, a bedside defibrillator, continuously monitors in-hospital patients at risk of sudden cardiac arrest, instantly detects the onset of a life-threatening heart rhythm, and, when appropriate, automatically delivers defibrillation shocks within seconds and without human intervention to re-establish the heart's normal rhythm. RHYTHMx ECD(TM) detection and defibrillation technology, a primary component of the Powerheart, has multiple applications, including use in existing standard bedside patient monitors widely used in hospitals throughout the world and in external defibrillators.

Cardiac Science has a strategic partnership with Medtronic Physio-Control, a division of Medtronic, Inc., the worldwide market leader in external defibrillator products, to distribute the Powerheart in the U.S., Canada, and nine European countries. Cardiac Science's global network consists of prominent distributors in 41 countries encompassing Asia, the Middle East, Europe, South America and North America. For more information, visit www.cardiacscience.com. Cardiac Science Inc. Consolidated Condensed Summary of Operations

                                      Three Months Ended December 31,
                                     ---------------------------------
                                           1999             1998
                                     -------------      --------------
Net loss from continuing operations  $ (2,890,867)      $ (1,278,167)
Net loss from discontinued
 operations                          $      ---         $   (562,720)
Net loss                             $ (2,890,867)      $ (1,840,887)
Net loss per share from continuing
 operations                          $      (0.25)      $      (0.22)
Net loss per share from discontinued
 operations                          $      ---         $       (0.9)
Net loss per share                   $      (0.25)      $      (0.31)
Weighted average number of shares
 used in the computation of net loss
 per share                             11,645,742          6,003,434


                                            Year Ended December 31,
                                     ---------------------------------
                                           1999             1998
                                     -------------      --------------
Net loss from continuing operations  $ (7,719,759)       $(3,787,704)
Net loss from discontinued
 operations                          $     ---           $  (651,030)
Net loss                             $ (7,719,759)       $(4,438,734)
Net loss per share from continuing
 operations                          $      (0.85)       $     (0.69)
Net loss per share from discontinued
 operations                          $     ---           $     (0.12)
Net loss per share                   $      (0.85)       $     (0.81)
Weighted average number of shares
 used in the computation of net loss
 per share                              9,112,564          5,459,793

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Cardiac Science cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements. Such forward looking statements include, but are not limited to the Powerheart's life-saving potential and the Company's ability to: improve patient-care; increase survival rates for in-hospital cardiac arrest victims; decrease patient recovery time; lessen patient debilitation and reduce patient-care costs. Other factors include, but are not limited to: hospital operations; market and clinical users' acceptance of new and existing products; impact of competitive products and pricing; and changing market conditions. Information on these and other factors is detailed in the Company's Form 10-K for the year ending December 31, 1999 and other documents filed with the Securities and Exchange Commission. The Powerheart, ECD and RHYTHMx ECD are trademarks of Cardiac Science Inc.